Scarica l'app Stockscreener
165.38
0.58%
0.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$164.42
Aprire:
$161.51
Volume 24 ore:
1.88M
Relative Volume:
0.96
Capitalizzazione di mercato:
$24.26B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
15.82
EPS:
10.453
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-7.25%
1M Prestazione:
-5.39%
6M Prestazione:
+32.31%
1 anno Prestazione:
+17.67%
Intervallo 1D:
$160.36
$165.61
Intervallo di 1 settimana:
$160.36
$178.41
Portata 52W:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
165.38 | 24.12B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,041.29 | 929.39B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.21 | 526.82B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.04 | 378.84B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
143.58 | 276.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
109.45 | 270.12B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
3 Biotech Stocks to Keep an Eye on in 2026 - Investing.com
40 Under 40: Kevin Conway, Biogen - Medical Marketing and Media
(BIIB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease - ADVFN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money? - AD HOC NEWS
Strong Cash Yield: Is Biogen Stock A Buy? - Trefis
Biogen Inc.: Can an Aging Neurology Giant Reinvent Itself Around Alzheimer’s? - AD HOC NEWS
Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st
June 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen Inc. (NASDAQ:BIIB) Short Interest Update - MarketBeat
Nordea Investment Management AB Has $18.20 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Wednesday when compared to competitors - MSN
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Genentech, NoNO, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell - Barchart.com
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha
Europe clears Biogen’s high-dose Spinraza regimen - The Pharma Letter
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - Sahm
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate the Biotech Pack? - AD HOC NEWS
Biogen (NASDAQ:BIIB) Shares Down 5.9%Time to Sell? - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Biogen falls after flagging $222 million charge to profit in Q4 - TradingView — Track All Markets
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence - BioSpace
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com Australia
What to Expect From Biogen's Next Quarterly Earnings Report - Barchart.com
Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4 - Nasdaq
Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus
Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs - GuruFocus
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly By Investing.com - Investing.com South Africa
Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share - MSN
Biogen Expects Q4 Expense of $222 Million - marketscreener.com
Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail
BiogenCharge to impact Q4 net income by $1.26 per shareSEC filing - marketscreener.com
Biogen’s Q4 preliminary EPS comes in below consensus By Investing.com - Investing.com Canada
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com
The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance
Biogen stock outlook remains positive as RBC reiterates Outperform rating By Investing.com - Investing.com UK
Biogen on the hunt for acquisition after $1B in cuts, 15% workforce reduction - The Business Journals
GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy - Nasdaq
Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference - Yahoo Finance
United States Biosimilars and Biologics Market to hit US$ 532.13 - openPR.com
Biogen (BIIB) Gains European Approval for High Dose SPINRAZA Reg - GuruFocus
Biogen Wins EU Approval for High-Dose Spinraza Regimen for Spinal Muscular Atrophy - marketscreener.com
Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial - TipRanks
Biogen says co received European Commission approval for high dose regimen of Spinraza - marketscreener.com
Biogen Announces European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy Treatment - Quiver Quantitative
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):